Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
NCT03081481
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
PRX302
Sponsor
Sophiris Bio Corp